Locally expressed IGF-1 propeptide improves function in induced dilated cardiomyopathy through blockade of myocardial fibrosis and SRF-dependent CTGF induction
Open Access
- 1 January 2012
- journal article
- research article
- Published by The Company of Biologists in Disease Models & Mechanisms
- Vol. 5 (4) , 481-91
Abstract
Summary: Cardiac fibrosis is critically involved in the adverse remodeling accompanying dilated cardiomyopathies (DCM), which leads to cardiac dysfunction and heart failure (HF). Connective tissue growth factor (CTGF), a profibrotic cytokine, plays a key role in this deleterious process. Some beneficial effects of IGF-1 on cardiomyopathy have been described, but its potential role in improving DCM is less well characterized. We investigated the consequences of expressing a cardiac-specific transgene encoding locally acting IGF-1 propeptide (mIGF-1) on disease progression in a mouse model of DCM. This mouse model of cardiac-specific and inducible SRF gene disruption mimics some forms of human DCM. Cardiac-specific mIGF-1 expression substantially extended the lifespan of SRF mutant mice, markedly improved cardiac functions and delayed both DCM and HF. These protective effects were accompanied by an overall improvement in cardiomyocyte architecture and a massive reduction of myocardial fibrosis with a concomitant amelioration of inflammation. At least part of the beneficial effects of mIGF-1 transgene expression were due to counteracting the strong SRF-dependent increase in CTGF expression within cardiomyocytes, resulting in the blockade of fibroblast proliferation and related myocardial fibrosis. These findings demonstrate that SRF plays a key role in the modulation of cardiac fibrosis through repression of cardiomyocyte CTGF expression in a paracrine fashion. They also explain how impaired SRF function observed in human heart failure contributes to promote fibrosis and adverse cardiac remodeling. Locally acting mIGF-1 efficiently protects the myocardium from these adverse processes, and may thus represent a cardiac therapeutic avenue to counter DCM.Keywords
This publication has 45 references indexed in Scilit:
- Cleavage of serum response factor mediated by enteroviral protease 2A contributes to impaired cardiac functionCell Research, 2011
- Regulation of pro‐inflammatory and pro‐fibrotic factors by CCN2/CTGF in H9c2 cardiomyocytesJournal of Cell Communication and Signaling, 2010
- CTGF Promotes Inflammatory Cell Infiltration of the Renal Interstitium by Activating NF-κBJournal of the American Society of Nephrology, 2009
- Serum response factor micromanaging cardiogenesisCurrent Opinion in Cell Biology, 2007
- Enhancing Repair of the Mammalian HeartCirculation Research, 2007
- Fibrosis in heart disease: understanding the role of transforming growth factor‐β1 in cardiomyopathy, valvular disease and arrhythmiaImmunology, 2006
- Temporally Controlled Onset of Dilated Cardiomyopathy Through Disruption of the SRF Gene in Adult HeartCirculation, 2005
- Lack of desmin results in abortive muscle regeneration and modifications in synaptic structureCell Motility, 2001
- Alterations at the Intercalated Disk Associated with the Absence of Muscle Lim ProteinJournal of Cell Biology, 2001
- Serum response factor is essential for mesoderm formation during mouse embryogenesisThe EMBO Journal, 1998